Antisynthetase Syndrome, the Microbiome and Interstitial Lung Disease: Is There a Gut–Lung Connection?

Could the Microbiome Influence Lung Disease in Antisynthetase Syndrome?

Antisynthetase syndrome is a systemic autoimmune disease defined by autoantibodies against aminoacyl-transfer RNA synthetases.

The syndrome can involve:

• interstitial lung disease

• inflammatory myopathy

• inflammatory arthritis

• Raynaud phenomenon

• mechanic’s hands

• fever

Among these manifestations, interstitial lung disease is one of the most clinically important and is a major determinant of morbidity and mortality. Recent longitudinal research continues to identify ILD as the principal driver of outcome in antisynthetase syndrome. (PubMed⁠)

The pulmonary phenotype is also heterogeneous.

Some patients develop relatively indolent chronic ILD.

Others develop progressive or severe disease.

This variability raises an important biological question:

Why do patients carrying different antisynthetase antibodies develop different patterns and trajectories of lung disease?

Genetics, autoantibody phenotype and immune pathways clearly matter.

But emerging microbiome research suggests that mucosal microbial communities may also interact with pulmonary immunity.

Importantly, however, the evidence in antisynthetase syndrome differs from the evidence in systemic sclerosis.

In systemic sclerosis-associated ILD, there is now substantial human research directly examining the gut microbiome.

In antisynthetase syndrome, the most disease-specific microbiome evidence currently relates to the lung microbiome, not the intestinal microbiome.

That distinction needs to remain clear.

What Is Antisynthetase Syndrome?

Antisynthetase syndrome is characterized by antibodies targeting enzymes responsible for attaching amino acids to transfer RNA.

The most familiar antibody is:

anti-Jo-1, directed against histidyl-tRNA synthetase.

Other antisynthetase antibodies include:

• anti-PL-7

• anti-PL-12

• anti-EJ

• anti-OJ

• anti-KS

• anti-Zo

• anti-Ha

The clinical phenotype differs considerably between antibody subgroups.

This is particularly relevant to the lungs.

For example, non-Jo-1 antibodies such as anti-PL-7 and anti-PL-12 have often been associated with a stronger pulmonary phenotype and may present with ILD even when muscle disease is subtle. Reviews of myositis-associated ILD have reported that ILD may be more frequent and severe in PL-7/PL-12 disease than in anti-Jo-1-positive disease. (PubMed⁠)

Therefore, antisynthetase syndrome should not be considered a single uniform pulmonary disorder.

Why Is ILD So Important in Antisynthetase Syndrome?

ILD may appear:

• before myositis

• simultaneously with other manifestations

• after the diagnosis of autoimmune disease

Some patients have little or no obvious muscle weakness.

This means the lung may be the organ that brings the patient to medical attention.

Common imaging patterns include:

• NSIP

• organizing pneumonia

• mixed NSIP/OP

• UIP in selected cases

The disease course can range from improvement with immunosuppression to recurrent or progressive ILD.

A 2026 longitudinal study specifically emphasizes that different trajectories of antisynthetase-associated ILD exist and that factors determining those trajectories remain incompletely understood. (PubMed⁠)

This uncertainty creates interest in additional biological modifiers—including microbial exposures.

Why Might the Microbiome Matter in an Autoimmune Lung Disease?

The immune system develops and functions in constant interaction with microorganisms.

Mucosal surfaces such as the:

• intestine

• oral cavity

• upper respiratory tract

• lower respiratory tract

are major sites of immune–microbial communication.

Microorganisms can influence immunity through:

• microbial antigens

• pattern-recognition receptors

• microbial metabolites

• epithelial-barrier signaling

• T-cell differentiation

• macrophage behavior

This creates a plausible model in which microbial communities might modify autoimmune disease activity.

But there is an important conceptual issue.

A microbiome association could mean that microbes contribute to disease.

Or disease could alter the microbiome.

Or treatment could alter both.

Therefore, microbiome studies should be viewed as the beginning of a mechanistic investigation—not automatic evidence of causation.

What Evidence Exists Specifically in Antisynthetase Syndrome?

The most direct disease-specific evidence comes from a study investigating the lung microbiome in antisynthetase syndrome-associated ILD.

Researchers analyzed bronchoalveolar lavage fluid from patients with antisynthetase syndrome and compared microbial profiles according to anti-Jo-1 status.

The study included:

• 6 anti-Jo-1-positive patients

• 17 non-Jo-1-positive patients

using 16S rRNA sequencing of BAL fluid. (PubMed⁠)

This is a very small study.

Nevertheless, it provides direct evidence that the pulmonary microbial environment may differ between antisynthetase phenotypes.

What Did the Lung Microbiome Study Find?

One of the major findings involved the genus:

Veillonella.

Veillonella abundance was significantly lower in the anti-Jo-1-positive group than in patients without anti-Jo-1 antibodies.

The investigators also identified associations between Veillonella and inflammatory cells in bronchoalveolar lavage.

Within the anti-Jo-1 group, Veillonella abundance showed:

• a strong negative correlation with macrophages

• positive correlations with eosinophils

• positive correlations with lymphocytes

• a strong positive relationship with Prevotella abundance

The investigators concluded that the lung microbiome differed according to antisynthetase phenotype and might interact with the inflammatory cellular environment. (PubMed⁠)

What Is Veillonella?

Veillonella is a genus commonly found in:

• the oral cavity

• upper respiratory tract

• gastrointestinal tract

Its presence in the lower airway is often interpreted within the broader context of microaspiration and migration of oral microorganisms into the lung.

However, Veillonella should not simply be labeled as either “good” or “bad.”

Its biological significance depends on:

• microbial community

• host immune status

• airway environment

• disease phenotype

The antisynthetase study therefore does not prove that lower Veillonella causes anti-Jo-1 lung disease.

It shows that microbial ecology and pulmonary immune phenotype may be linked.

Why Is Prevotella Interesting?

Prevotella is another common mucosal genus found in the oral and gastrointestinal microbiota.

It has attracted substantial attention in autoimmune diseases, including rheumatoid arthritis.

In the antisynthetase study, Veillonella correlated strongly with Prevotella.

This could reflect shared ecological conditions within the airway.

Again, this does not establish that either organism causes ILD.

But it suggests the lower respiratory microbiome may behave as an ecosystem rather than a collection of unrelated bacteria.

The Lung Microbiome Is Not the Same as the Gut Microbiome

This distinction is essential.

A BAL study tells us about microorganisms present in the pulmonary environment.

It does not tell us directly what is happening in the intestinal microbiome.

The microbiome should therefore be considered across several connected compartments:

oral microbiome
↓
airway microbiome

and potentially:

gut microbiome
↓
systemic immune/metabolic signaling
↓
lung

These are related concepts but not identical mechanisms.

What About the Gut Microbiome in Antisynthetase Syndrome?

This is where evidence becomes much thinner.

At present, robust human studies specifically characterizing the gut microbiome in well-defined antisynthetase syndrome cohorts are lacking.

Some relevant clues come from broader inflammatory myopathy research.

A 2023 metagenomic study in patients with idiopathic inflammatory myopathies found intestinal dysbiosis and demonstrated additional microbial differences between rapidly progressive ILD and chronic ILD.

That cohort included patients with myositis-related autoantibodies, including antisynthetase antibodies, but it was not designed as a dedicated antisynthetase gut-microbiome study.

Therefore, it provides supportive context—not definitive antisynthetase-specific evidence.

Why Is This Evidence Gap Important?

It prevents us from making claims such as:

“Patients with antisynthetase syndrome have a specific gut microbiome pattern.”

That has not yet been demonstrated convincingly.

Likewise, there is no established gut microbial signature specific to:

• anti-Jo-1

• anti-PL-7

• anti-PL-12

• anti-EJ

• anti-OJ

Much more research is required.

Could Different Autoantibodies Be Associated With Different Microbiomes?

This is an intriguing possibility.

The pulmonary phenotype differs between antisynthetase antibodies.

If microbial ecology interacts with the immune system, different autoantibody phenotypes might theoretically show different microbial patterns.

The anti-Jo-1 lung microbiome study provides a preliminary signal supporting this concept because anti-Jo-1-positive and non-Jo-1 patients had different airway microbial characteristics. (PubMed⁠)

Future studies should therefore stratify patients by antibody rather than combining all antisynthetase syndrome patients into one group.

How Could Microbes Influence Antisynthetase ILD?

Several mechanisms are biologically plausible.

1. Mucosal Immune Activation

Antisynthetase syndrome is an autoimmune disease.

Mucosal surfaces are major sites of immune activation.

Repeated microbial exposure could influence:

• innate immune signaling

• antigen presentation

• T-cell differentiation

• cytokine production

In genetically and immunologically susceptible individuals, chronic mucosal activation might contribute to systemic autoimmunity.

This remains a hypothesis.

2. Pattern-Recognition Receptors

Microbial molecules interact with receptors such as:

• Toll-like receptors

• NOD-like receptors

These receptors detect microbial structures and activate inflammatory pathways.

For example:

TLR signaling → NF-κB activation → inflammatory cytokines

These pathways can influence pulmonary macrophages and epithelial cells.

Persistent inappropriate activation might theoretically contribute to autoimmune lung injury.

3. Macrophage–Microbiome Interaction

The antisynthetase lung microbiome study found a strong relationship between Veillonella abundance and macrophage proportions.

Macrophages are particularly important in ILD because they can participate in:

• innate immune responses

• tissue repair

• fibroblast signaling

• extracellular-matrix remodeling

Different microbial environments could theoretically alter macrophage phenotype.

Whether this contributes to disease severity remains unknown. (PubMed⁠)

4. Epithelial Injury

Repeated epithelial injury is a major component of many ILDs.

Microbial products can interact directly with respiratory epithelial cells.

Depending on the context, these signals could influence:

• epithelial inflammation

• barrier integrity

• cytokine production

• repair responses

In autoimmune ILD, these processes may interact with systemic immune activity.

5. Oral–Lung Microbial Migration

The lungs are continuously exposed to small amounts of material originating from the upper airway.

Microaspiration occurs even in healthy people.

The lower-airway microbiome is therefore partly shaped by:

• immigration of oral microorganisms

• elimination through cough and mucociliary clearance

• local growth conditions

Veillonella and Prevotella are both organisms frequently associated with oral microbial communities.

Their presence in BAL fluid may therefore reflect oral–lung microbial trafficking.

Could Reflux and Microaspiration Be Relevant?

Potentially.

Microaspiration can influence the lower-airway microbial environment.

Patients with chronic autoimmune disease may also experience:

• reflux

• esophageal dysfunction

• medication-related gastrointestinal symptoms

However, reflux has not been established as a primary driver of antisynthetase syndrome ILD.

The concept should therefore remain separate from the immune microbiome hypothesis.

6. Gut-Derived Microbial Metabolites

Even without gut bacteria reaching the lungs, microbial metabolites may enter circulation.

These include:

• SCFAs

• tryptophan metabolites

• bile-acid metabolites

• microbial peptides

These molecules can affect immune-cell behavior at distant sites.

This provides the major theoretical mechanism for a gut–lung axis in antisynthetase syndrome.

But direct evidence remains limited.

Short-Chain Fatty Acids

SCFAs such as:

• butyrate

• propionate

• acetate

can influence:

• regulatory T cells

• macrophages

• intestinal-barrier function

• inflammatory signaling

This makes them plausible mediators in autoimmune disease.

However, no clinical study has demonstrated that manipulating SCFAs modifies antisynthetase ILD.

Tryptophan Metabolism

Microbial metabolism of tryptophan can generate indole derivatives that influence the aryl hydrocarbon receptor, or AhR.

AhR signaling participates in:

• mucosal immunity

• Treg/Th17 balance

• epithelial-barrier regulation

These pathways are relevant to systemic autoimmunity.

But they have not yet been specifically validated as therapeutic targets in antisynthetase syndrome.

Molecular Mimicry

Another theoretical mechanism is molecular mimicry.

Microbial proteins can sometimes resemble host proteins.

This may contribute to abnormal immune recognition in susceptible individuals.

Because antisynthetase syndrome targets intracellular enzymes involved in protein translation, researchers may eventually investigate whether microbial antigen exposure participates in loss of tolerance.

At present, this remains speculative.

Why Could the Lung Be a Site of Autoimmune Initiation?

One interesting possibility in autoimmune ILD is that the lung is not merely a target organ.

It may also participate in the development of autoimmune responses.

Respiratory epithelial injury, environmental exposure and microbial stimulation could create conditions in which intracellular proteins are released or modified.

This could contribute to antigen presentation and autoimmune activation.

The concept resembles mucosal-origin models proposed in rheumatoid arthritis.

Whether this specifically contributes to antisynthetase autoantibody development is still uncertain.

Environmental Exposures May Interact With the Microbiome

The respiratory tract is continuously exposed to:

• air pollution

• occupational particles

• tobacco smoke

• infectious agents

• organic antigens

These exposures can modify:

• airway epithelial integrity

• pulmonary immunity

• lung microbiota

Therefore, future research may need to consider the interaction between:

environment + microbiome + immune phenotype + genetics

rather than looking at microbes in isolation.

Could the Microbiome Explain Anti-Jo-1 Versus PL-7/PL-12 Disease?

Not yet.

We know that different antisynthetase antibodies are associated with different clinical patterns.

Anti-PL-7 and anti-PL-12 disease frequently has prominent pulmonary involvement, while anti-Jo-1 disease may have a different balance of myositis, arthritis and ILD. (PubMed⁠)

But there are insufficient microbiome data to determine whether microbial factors explain these differences.

This would be a valuable research direction.

Can the Microbiome Predict ILD Progression?

No validated microbiome biomarker currently predicts the trajectory of antisynthetase-associated ILD.

Recent 2026 research demonstrates that antisynthetase ILD follows different longitudinal trajectories and that predicting clinical course remains a major challenge. (PubMed⁠)

Microbial biomarkers might eventually contribute to such models.

But that is a future possibility.

Can a Commercial Stool Test Tell Whether Antisynthetase ILD Will Progress?

No.

There is currently no commercial microbiome test validated to predict:

• development of antisynthetase syndrome

• presence of ILD

• progression of ILD

• relapse

• response to immunosuppression

• prognosis

Research microbiome sequencing should not be confused with commercial stool testing.

Can BAL Microbiome Testing Be Used Clinically?

Not currently for routine antisynthetase management.

BAL may be clinically useful in selected ILD patients for specific diagnostic questions, particularly when infection or other competing diagnoses are considered.

But performing BAL purely to characterize the microbiome is currently a research strategy.

There is no validated BAL microbiome threshold that dictates antisynthetase treatment.

Do Probiotics Treat Antisynthetase ILD?

No clinical evidence supports probiotics as treatment for antisynthetase syndrome-associated ILD.

No probiotic has been shown to:

• improve FVC

• improve DLCO

• prevent progression

• reduce relapses

• improve survival

Probiotics may have separate gastrointestinal indications.

They should not be promoted as immunosuppressive or antifibrotic treatment.

What About Prebiotics or Butyrate?

Theoretical microbiome pathways involving SCFAs are scientifically interesting.

But there are currently no clinical trials demonstrating that:

• fiber manipulation

• prebiotics

• butyrate

• postbiotics

modify antisynthetase ILD outcomes.

This remains experimental.

Does Treating Gut Dysbiosis Reduce Autoantibodies?

There is no evidence that a microbiome intervention reliably eliminates:

• anti-Jo-1

• anti-PL-7

• anti-PL-12

• other antisynthetase antibodies

or treats the underlying syndrome.

Claims that “healing the gut” can eliminate antisynthetase syndrome are not supported by current clinical evidence.

What Treatments Are Actually Established?

Antisynthetase ILD generally requires specialist immunomodulatory treatment.

The evidence base is imperfect because randomized trials specifically dedicated to antisynthetase ILD remain limited, but current management uses combinations of corticosteroids and steroid-sparing immunosuppressive agents according to disease severity and phenotype. (PubMed⁠)

Potential therapies may include, depending on the clinical context:

• mycophenolate

• tacrolimus or other calcineurin inhibitors

• rituximab

• cyclophosphamide

• additional immunomodulatory strategies

Treatment needs to be individualized by clinicians experienced in autoimmune ILD.

Relapse and Recurrence Matter

Even after initial improvement, antisynthetase ILD can recur.

A 2026 study specifically examined factors associated with recurrence of antisynthetase-associated ILD, reinforcing that long-term disease monitoring remains important. (PubMed⁠)

This is another reason experimental microbiome interventions should not replace established follow-up.

Patients require serial assessment of:

• symptoms

• pulmonary function

• imaging where appropriate

• oxygenation

• autoimmune disease activity

Functional and Integrative Medicine Perspective

Antisynthetase syndrome is a useful example of how integrative care should be structured.

The central disease must first be correctly phenotyped.

That means identifying:

• antibody subtype

• HRCT pattern

• lung-function trajectory

• myositis activity

• arthritis

• oxygenation

• progression risk

Then broader health factors can be addressed.

These may include:

• nutritional status

• gastrointestinal symptoms

• reflux

• metabolic health

• muscle preservation

• sleep

• physical activity

• environmental exposures

• medication effects

This is a more defensible model than attempting to treat the autoimmune ILD through the microbiome alone.

Why Muscle Health Is Especially Important

Unlike many other ILDs, antisynthetase syndrome may directly impair skeletal muscle.

This creates a particularly important interaction between:

lung function + muscle function + nutrition + rehabilitation

A patient’s exercise limitation may reflect both:

• pulmonary impairment

• inflammatory muscle weakness

Preserving nutritional status and muscle mass is therefore especially important.

Overly restrictive diets intended to “heal the microbiome” could be counterproductive in patients already at risk of muscle loss.

What We Know

Current evidence supports several conclusions.

We know that:

• ILD is a major determinant of outcome in antisynthetase syndrome

• pulmonary phenotype varies according to antisynthetase antibody

• the lower-airway microbiome may differ according to anti-Jo-1 status

• Veillonella abundance differed between anti-Jo-1-positive and non-Jo-1 patients in one BAL study

• airway microbial abundance correlated with inflammatory-cell populations

(PubMed⁠)

These observations make microbial–immune interactions a credible research target.

What We Do Not Know

We do not yet know whether:

• gut dysbiosis causes antisynthetase syndrome

• the gut microbiome differs consistently between Jo-1 and PL-7/PL-12 disease

• airway microbiome changes precede ILD

• Veillonella contributes causally to pulmonary injury

• microbiome modification changes FVC

• probiotics reduce relapse

• butyrate changes disease progression

• commercial stool testing predicts prognosis

The disease-specific microbiome literature remains small.

The Major Limitation: Sample Size

The most directly relevant lung microbiome study involved only:

• 6 anti-Jo-1-positive patients

• 17 non-Jo-1 patients

(PubMed⁠)

Such a small cohort cannot establish a universal microbial signature.

Larger multicenter studies are necessary.

What Should Future Research Look Like?

An ideal antisynthetase microbiome study would recruit a large international cohort stratified by:

• anti-Jo-1

• anti-PL-7

• anti-PL-12

• anti-EJ

• other ARS antibodies

and characterize:

• stool metagenome

• oral microbiome

• lung microbiome

• serum metabolome

• immune phenotype

Patients would then undergo longitudinal assessment of:

• FVC

• DLCO

• HRCT

• treatment response

• relapse

• progressive pulmonary fibrosis

• survival

This could reveal whether microbial signatures are simply associated with established disease or actually precede different clinical trajectories.

From Gut–Lung Axis to Mucosal Network

Ultimately, antisynthetase syndrome may require a broader concept than the gut–lung axis.

A more realistic model may be:

gut microbiome
↕
systemic immunity
↕
oral microbiome
↕
lung microbiome
↕
pulmonary epithelial injury
↕
autoimmune response

This can be thought of as a mucosal–immune–lung network.

Such a model better reflects the complexity of autoimmune lung disease.

What Does This Mean for Patients Today?

Microbiome research is scientifically interesting, but it is not currently a reason to delay established treatment.

A patient with antisynthetase syndrome and ILD needs appropriate assessment of:

• pulmonary disease severity

• antibody phenotype

• lung-function trajectory

• HRCT findings

• oxygen requirement

• treatment response

• possible relapse or progression

Gastrointestinal symptoms, nutritional status and lifestyle factors also deserve attention.

But there is currently no evidence-based “antisynthetase microbiome protocol.”

Conclusion

The microbiome may ultimately contribute to our understanding of antisynthetase syndrome-associated interstitial lung disease.

The strongest disease-specific evidence currently comes from the lung microbiome, where a small bronchoalveolar lavage study found differences between anti-Jo-1-positive and non-Jo-1 patients and identified relationships between Veillonella, Prevotella and pulmonary immune-cell populations. (PubMed⁠)

That finding is intriguing.

But the evidence remains early.

We do not yet have a well-defined antisynthetase gut microbiome signature, nor evidence that treating intestinal dysbiosis changes the course of ILD.

This distinction is particularly important because microbiome research can easily be overinterpreted.

The appropriate conclusion is not:

“Antisynthetase ILD is caused by the gut.”

It is:

“Mucosal microbial environments may interact with immune and pulmonary phenotypes in antisynthetase syndrome, and this interaction deserves much more rigorous investigation.”

Future research integrating the gut, oral and lung microbiomes with metabolomics, autoantibody phenotype and longitudinal lung outcomes may help explain why antisynthetase-associated ILD behaves so differently between patients.

That could eventually lead to new biomarkers or therapeutic targets.

For now, microbiome science should complement—not replace—the established framework of autoimmune ILD care.

About Dr. Samar Shadly

Dr. Samar Shadly is a Consultant Pulmonologist and Certified Functional Medicine Practitioner, with advanced subspecialty training in interstitial lung disease, pulmonary fibrosis, pulmonary hypertension and lung transplantation at the University of Toronto.

Her clinical and academic interests include Integrative and Functional Pulmonology, autoimmune-associated ILD, the gut–lung axis, lung microbiome, nutrition, metabolic health and emerging microbial mechanisms in chronic lung disease.

Living With Antisynthetase Syndrome and ILD?

If you have anti-Jo-1, PL-7, PL-12 or another antisynthetase antibody with interstitial lung disease and would like a comprehensive assessment combining specialist pulmonary expertise with an evidence-based functional and integrative perspective, you can explore the available online consultation options.

The assessment can consider your pulmonary disease together with relevant nutritional, gastrointestinal, metabolic and lifestyle factors while remaining anchored to evidence-based ILD treatment.

Contact us through the consultation page or WhatsApp to learn more.

Functional and integrative care is intended to complement—not replace—appropriate pulmonary, rheumatological and immunomodulatory treatment.

Medical Disclaimer: This article is educational and does not constitute individualized medical advice. Antisynthetase syndrome-associated ILD requires appropriate specialist evaluation and treatment.